Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
Holding EOLS?
Track your performance easily
EOLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.25 - $17.82
Previous CloseN/A
Volume344.54K
Average Volume (3M)613.62K
Market Cap
$671.84M
Enterprise Value$1.07B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Feb 26, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,321,490
10 Day Avg. Volume786,537
30 Day Avg. Volume613,622
Standard Deviation0.25
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.71
Price to Cash Flow (P/CF)-29.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit7.60
Enterprise Value/Ebitda-26.98
Forecast
1Y Price Target
$23.50Price Target Upside123.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Evolus News
PremiumCompany Announcements
Evolus, Inc. Reports Strong Q3 2024 Growth
Bulls Say, Bears Say
Bulls Say
Consumer LoyaltyThe number of consumers enrolled in the Evolus Rewards loyalty program exceeded 1 million, highlighting strong consumer loyalty and effective marketing strategies.
Market ExpansionEvolus becomes one of only five companies in the EU offering both a neurotoxin and an injectable HA gel line, enhancing its market position.
Revenue Growth PotentialThe launch of the fillers franchise in 2025/2026 is expected to drive additional top line growth and operating success.
Bears Say
Financial Performance3Q24 non-GAAP EPS was wider than expected due to higher SG&A spending and lower Jeuveau sales.
Market PerceptionThere is investor perception of issues due to significant stock decline, partly attributed to Medytox selling overhang.
Revenue ForecastConcerns exist about another potential quarter of tough comparison in revenues, leading to a slight decrease in the revenue forecast for 4Q24.
---
Ownership Overview
3.36% Insiders
10.18% Mutual Funds
0.86% Other Institutional Investors
74.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $9.25 and its highest was $17.82 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $671.84M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Feb 26, 2025 which is in 39 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Nov 06, 2024. The company reported -$0.162 earnings per share for the quarter, missing the consensus estimate of -$0.123 by -$0.039.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is 0.02.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 63,321,490 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -$0.162 in its last earnings report, missing expectations of -$0.123. Following the earnings report the stock price went down -14.991%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
---
Evolus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.50 (123.60% Upside)
$23.50 (123.60% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 226.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.78%
12-Months-Change
Fundamentals
Return on Equity
-941.60%
Trailing 12-Months
Asset Growth
36.70%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
---
EOLS Company Deck
---
EOLS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful product expansion, and positive long-term financial projections. However, it also addressed challenges such as operating losses, cash burn, and market softness in the filler category. The company's strategic initiatives and product launches are expected to drive future growth.Read More>---
EOLS Stock 12 Month Forecast
Average Price Target
$23.50
▲(123.60% Upside)
Technical Analysis
Revance Therapeutics
―
Veru
―
Syndax Pharmaceuticals
―
Fate Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering EOLS
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+4.88%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +4.88% per trade.
---